How GLP-1 analogs are reshaping diabetes care and obesity treatment and unlocking potential in cardiovascular, inflammatory, ...

Eli Lilly’s shares shot up 11% pre-market on Thursday after orforglipron became the first small-molecule GLP-1 drug to ace a ...

Going forward, Pfizer said it is shifting its focus to the development of GIPR receptors and other earlier obesity programs. As of midday trading, Pfizer’s stock is slightly up. GLP-1 rivals Eli Lilly ...

Pooled annual prevalence of GLP-1 RA use was 0.1 percent from 2018 to 2021 and increased to 0.4 percent by 2022.

Both glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) ...

DA-1726 acts as a dual agonist of GLP-1 receptors (GLP1R ... words or other comparable terminology (as well as other words or expressions referencing future events, conditions or circumstances ...

Liraglutide Offers Long-Term Stability and Expands Hydreight’s Comprehensive GLP-1 Weight Management PortfolioVANCOUVER, British Columbia and LAS VEGAS, April 15, 2025 (GLOBE NEWSWIRE) -- Hydreight ...

whose drug Zepbound activates the GLP-1 and GIP receptors, currently dominate the obesity drug market. But both products are administered as once-weekly injections. Pfizer is part of a growing ...

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced the decision to discontinue development of danuglipron (PF-06882961), an oral glucagon-like peptide-1 (GLP-1) receptor agonist ...

The annual prevalence increased to 0.4% by 2022, with an estimated 854,728 adults without diabetes using GLP-1 RAs. HealthDay News — Among US adults without diabetes, the use of glucagon-like ...